Healthcare
SILENCE THERAPEUTICS PLC
Ticker: SLN
|
Exchange: XS
|
Composite FIGI: BBG000R9V764
Total Alternative Signals
1signals tracked
Weighted Sentiment
+0.90weighted index
Avg Materiality Score
5.0/ 5.0 scale
Signal Distribution
1▲|0■|0▼
Alternative Data Signal Feed
Unlock Alternative Signals Feed
Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for SILENCE THERAPEUTICS PLC. Programmatic API and Webhooks available.
Earnings ReportBullish
Filing Date: 2026-06-12
Signal Event Report - FIGI BBG000R9V764
Silence Therapeutics presented positive follow-up data for divesiran in polycythemia vera at EHA 2026, demonstrating durable efficacy and a potential best-in-class profile. This clinical advancement strengthens the company's pipeline and market position.
Quantitative Investment Thesis
The positive Phase 1 data for divesiran significantly de-risks this key asset and enhances its commercial potential, strengthening the long-term investment case for SLN as a leader in siRNA therapies. This could lead to accelerated development and potential partnerships, driving future revenue growth.
Materiality & Sentiment Scores
Sentiment: 0.9
Materiality: 5 / 5
Source Document: https://finance.yahoo.com/sectors/healthcare/articles/silence-therapeutics-highlights-data-eha-113000297.html?.tsrc=rss